Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced brea...
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
About this item
Full title
Author / Creator
Xu, Binghe , Zhang, Qingyuan , Zhang, Pin , Hu, Xichun , Li, Wei , Tong, Zhongsheng , Sun, Tao , Teng, Yuee , Wu, Xinhong , Ouyang, Quchang , Yan, Xi , Cheng, Jing , Liu, Qiang , Feng, Jifeng , Wang, Xiaojia , Yin, Yongmei , Shi, Yanxia , Pan, Yueyin , Wang, Yongsheng , Xie, Weimin , Yan, Min , Liu, Yunjiang , Yan, Ping , Wu, Fei , Zhu, Xiaoyu , Zou, Jianjun and DAWNA-1 Study Consortium
Publisher
New York: Nature Publishing Group US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Nature Publishing Group US
Subjects
More information
Scope and Contents
Contents
Blockade of the cyclin-dependent kinase 4 and 6 pathway has been shown to be effective in the treatment of hormone receptor-positive advanced breast cancer (ABC). We report the interim results of DAWNA-1 (
NCT03927456
), a double-blind, randomized, phase 3 trial of dalpiciclib (a new cyclin-dependent kinase 4 and 6 inhibitor) plus fulvestrant...
Alternative Titles
Full title
Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial
Authors, Artists and Contributors
Author / Creator
Zhang, Qingyuan
Zhang, Pin
Hu, Xichun
Li, Wei
Tong, Zhongsheng
Sun, Tao
Teng, Yuee
Wu, Xinhong
Ouyang, Quchang
Yan, Xi
Cheng, Jing
Liu, Qiang
Feng, Jifeng
Wang, Xiaojia
Yin, Yongmei
Shi, Yanxia
Pan, Yueyin
Wang, Yongsheng
Xie, Weimin
Yan, Min
Liu, Yunjiang
Yan, Ping
Wu, Fei
Zhu, Xiaoyu
Zou, Jianjun
DAWNA-1 Study Consortium
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2594295783
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2594295783
Other Identifiers
ISSN
1078-8956
E-ISSN
1546-170X
DOI
10.1038/s41591-021-01562-9
